Time filter

Source Type

A solid dispersion containing Desmodium Styracifolium (Osb.) Merr. flavonoids, method of preparing same and use thereof. The Desmodium Styracifolium (Osb.) Merr. flavonoids are alcohol extract of Desmodium Styracifolium (Osb.) Merr., and the solid dispersion is used for preparing a drug for treating urinary tract calculi.


Patent
Humanwell Healthcare Group Co., Hubei Bio Pharmaceutical Industrial Technological Institute Inc. and Medshine Discovery Inc. | Date: 2015-03-30

Disclosed is a series of analogues of 4H-pyrazolo[1,5-]benzimidazole compound as PARP inhibitors. In particular, disclosed in the invention is a compound as shown by formula (I) or a pharmaceutically acceptable salt thereof as a PARP inhibitor.


Patent
Hubei Bio Pharmaceutical Industrial Technological Institute Inc., Humanwell Healthcare Group Co. and Medshine Discovery Inc. | Date: 2017-02-15

Disclosed is a series of analogues of 4H-pyrazolo[1,5-a]benzimidazole compound as PARP inhibitors. In particular, disclosed in the invention is a compound as shown by formula (I) or a pharmaceutically acceptable salt thereof as a PARP inhibitor.


China's blood product market size mushroomed in 2016 under the impetus of liberalization of limited-price policy, price rises in varying degrees and lot release volume growth for blood products in 2015, estimated to reach RMB23.8 billion throughout the year, up 16.7% from 2015. China's blood product industry will develop at full speed boosted by downstream demand, accompanied by a steady rise in the number of plasma stations and consolidated profit margin improvement of plasma. The market size is expected to hit RMB47.5 billion in 2021. Main features of blood product industry in China 2016 are shown as below: 1. As plasma supply increases, supply-demand balance can be seen in 2025 China's plasma collection volume has been increasing over recent years driven by blood product price deregulation and accelerated establishment of new plasma stations. In 2016, 6,964 tons of plasma was collected in China, up 19.8% year on year. Despite continuous growth, plasma collection volume still cannot meet the ever-increasing market demand. In the future, China will see plasma collection volume shooting up propelled by a growing number of plasma collection stations and is expected to achieve balance between plasma supply and demand in 2025. 2. A steady increase in lot release volume of main products So far, Chinese blood products are still dominated by human albumin and human immunoglobulin for intravenous injection, which take an over 70% blood product market share. In 2016, human albumin and human immunoglobulin (pH4) for intravenous injection registered respective lot release volumes of 39.31 million bottles (10g/bottle) and 10.89 million bottles (2.5g/bottle), up 17.8% and 27.4% respectively year on year. In addition, lot release volumes of domestic blood products in short supply such as blood coagulation factor VIII, human immunoglobulin and human prothrombin complex also witnessed substantial growth in 2016, respectively 38.0%, 143.8% and 20%. 3. R&D efforts intensified for new products; comprehensive utilization of plasma to be raised At present, Chinese blood product enterprises can separate a maximum of 11 varieties of blood products from the plasma, 3-4 varieties for general firms, indicating an extremely low rate of comprehensive utilization of plasmas. To solve the problem, Chinese blood product enterprises are accelerating the development of new products, hoping to improve comprehensive utilization of plasma. Blood coagulation factor VIII, for example, Guizhou Taibang Biological Products Co., Ltd., Jiangxi Boya Bio-Pharmaceutical Co., Ltd., Beijing Tiantan Biological Products Co., Ltd., Zhenxing Biopharmaceutical & Chemical Co., Ltd., Wuhan Zhongyuan Ruide Biological Products Co., Ltd. etc. are actively conducting clinical trials of blood coagulation factor VIII and expected to achieve mass production in next two years. 4 Plasma-oriented pattern continues Blood product industry relies heavily on plasma materials - the number of plasma stations directly influences plasma collection volume, which then affects raw material supply of blood product enterprises. Therefore, the number of plasma stations and plasma collection volume determine corporate position in industry. There are over 30 blood product manufacturing enterprises in China, but only more than 20 are able to maintain normal production. Among them, Hualan Biological Engineering,Inc., Shanghai RAAS Blood Products Co., Ltd. and China Biologic Products, Inc. boast relatively high volume of plasma collection, altogether accounting for 39.6% of total plasma collections in 2016. The report highlights the following: - Analysis on development of China blood product industry, including status quo, policy environment, market supply & demand, market size, market structure and competition pattern; - Analysis on 8 market segments of China blood product industry, including development status, competition pattern and trends; - Analysis on 13 major enterprises, including operation, blood product business, etc.; - Summary & forecast and trends. - The Chinese Version of this Report is Available on Request. 1 Overview of Truck Industry 1.1 Definition and Classification 1.2 Introduction of Technologies 1.3 Latest Policies during 2016-2017 1.3.1 Enforcement of National V Emission Standards 1.3.2 GB1589 Standards and "921 New Reform" 1.3.3 Ban on Low-Speed Trucks 1.3.4 Compulsory Installation of ABS Device for Trucks 1.3.5 Yellow Label' Vehicle Elimination Continues 1.4 Self-driving and Connected Truck 1.4.1 Truck Self-driving 1.4.2 Truck Telematics 2 Truck Market as a Whole 2.1 Ownership 2.2 Production and Sales 2.2.1 Production 2.2.2 Sales 2.3 Market Structure 2.4 Import & Export 2.5 Competitive Pattern 3 Truck Market Segments 3.1 Heavy Truck 3.1.1 Production and Sales 3.1.2 Competitive Landscape 3.1.3 Natural Gas Heavy Truck 3.1.4 High-end Heavy Truck 3.2 Medium Truck 3.2.1 Production and Sales 3.2.2 Competitive Landscape 3.3 Light Truck 3.3.1 Production and Sales 3.3.2 Competitive Landscape 3.4 Mini Truck 3.4.1 Production and Sales 3.4.2 Competitive Landscape 5 Key Companies 5.1 FAW Jiefang Automotive Co., Ltd. 5.1.1 Profile 5.1.2 Production and Sales 5.1.3 Launch of New Products 5.1.4 Manufacturing Bases 5.1.5 Developments 5.2 China National Heavy Duty Truck Group Co., Ltd. (SINOTRUK) 5.2.1 Profile 5.2.2 Operation 5.2.3 Production and Sales 5.2.4 Heavy-duty Truck Business 5.3 Dongfeng Motor Corporation 5.3.1 Profile 5.3.2 Operation 5.3.3 Truck Business 5.3.4 Capacity Distribution 5.3.5 Developments 5.4 Beiqi Foton Motor Co., Ltd. 5.4.1 Profile 5.4.2 Operation 5.4.3 Heavy-duty Truck Business 5.4.4 Production Capacity 5.4.5 Progress in Launch of New Products 5.5 Shaanxi Automobile Group Co., Ltd. 5.5.1 Profile 5.5.2 Major Products 5.5.3 Heavy-duty Truck Business 5.5.4 Developments 5.6 Anhui Jianghuai Automobile Group Corp.,Ltd. 5.6.1 Profile 5.6.2 Operation 5.6.3 Production and Sales 5.6.4 Capacity Distribution 5.6.5 Developments 5.7 Hualing Xingma Automobile (Group) Co., Ltd. 5.7.1 Profile 5.7.2 Operation 5.7.3 Truck Business 5.7.4 Production and Sales 5.8 QingLing Motors (Group) Co., Ltd. 5.8.1 Profile 5.8.2 Operation 5.8.3 Truck Business 5.9 Jiangling Motors Co., Group 5.9.1 Profile 5.9.2 Jiangling Holdings Limited 5.9.3 Production and Sales 5.9.4 Capacity Distribution 5.9.5 Developments 5.10 SAIC GM Wuling (SGMW) 5.10.1 Profile 5.10.2 Key Business 5.10.3 Production and Sales 5.10.4 Manufacturing Bases 5.11 SAIC-IVECO Hongyan 5.11.1 Profile 5.11.2 Heavy-duty Truck Business 5.11.3 Sales Goal for 2017 5.12 Hubei Tri-Ring Special Vehicle Co., Ltd. 5.12.1 Profile 5.12.2 Truck Business 5.12.3 Production and Sales 5.12.4 Developments 5.13 XCMG Automobile 5.13.1 Profile 5.13.2 Heavy-duty Truck Business 5.13.3 Capacity Distribution 5.14 GAC HINO Motors Co., Ltd. 5.14.1 Profile 5.14.2 Operation 5.14.3 Heavy-duty Truck Business 5.14.4 Production Capacity 5.15 Zhejiang Feidie Automobile Manufacturing Co., Ltd. 5.15.1 Profile 5.15.2 Truck Business 5.16 Baotou Bei Ben Heavy-Duty Truck Co., Ltd. 5.16.1 Profile 5.16.2 Heavy-duty Truck Business 5.17 Shanxi Dayun Automobile Manufacturing Co., Ltd 5.17.1 Profile 5.17.2 Truck Business List of Charts - Classification of Truck (Freight Vehicle) - Applications of Truck - Technology Introduction of Key Heavy Truck Manufacturers in China - Schedule for Implementation of China's Motor Vehicle National V Emission Standards - Comparison of China's National IV and V Emission Standards - Standards for Identifying Oversize and Overload of Highway Freight Vehicles (in 6-axle case) - Policies and Regulations on Commercial Vehicle Telematics - Survey on Truck Telematics at Home and Abroad - China's Truck Ownership, 2010-2021E - China's Truck Output, 2010-2021E - China's Truck Sales, 2010-2021E - China's Truck Output and Growth Rate by Product, 2016-2017 - China's Truck Sales and Growth Rate by Product, 2016-2017 - China's Monthly Truck Exports, 2016 - China's Monthly Truck Imports, 2016 - Sales Volume and Market Share of Top10 Truck Manufacturers in China, 2016-2017 - China's Complete Heavy Truck Output and Sales Volume, 2010-2021E - China's Incomplete Heavy Truck Output and Sales Volume, 2010-2021E - China's Semi-trailer Towing Vehicle Output and Sales Volume, 2010-2021E - Sales Volume and Market Share of Top10 Complete Heavy Truck Manufacturers in China, 2016-2017 - Sales Volume and Market Share of Top10 Incomplete Heavy Truck Enterprises in China, 2016-2017 - Sales Volume and Market Share of Top10 Semi-trailer Towing Vehicle Manufacturers in China, 2016-2017 - Sales Volume of Natural Gas Heavy Trucks in China, 2014-2021E - Major Natural Gas Heavy Truck Manufacturers in China - High-end Heavy Trucks Launched by Enterprises in China - China's Complete Medium Truck Output and Sales Volume, 2010-2021E - China's Incomplete Medium Truck Output and Sales Volume, 2010-2021E - Sales Volume and Market Share of Top10 Complete Medium Truck Manufacturers in China, 2016-2017 - Sales Volume and Market Share of Top10 Incomplete Medium Truck Manufacturers in China, 2016-2017 - China's Complete Light Truck Output and Sales Volume, 2010-2021E - China's Incomplete Light Truck Output and Sales Volume, 2010-2021E - Sales Volume and Market Share of Top10 Complete Light Truck Manufacturers in China, 2016-2017 - Sales Volume and Market Share of Top10 Incomplete Light Truck Manufacturers in China, 2016-2017 - China's Complete Mini Truck Output and Sales Volume, 2010-2021E - China's Incomplete Mini Truck Output and Sales Volume, 2010-2021E - Sales Volume and Market Share of Top10 Complete Mini Truck Manufacturers in China, 2016-2017 - Automotive Industry Chain - Cost Structure of Truck Industry - Transmission Supply of Major Heavy Truck Manufacturers in China - China's Galvanized Sheet (Strip) Output and Sales Volume, 2010-2017 - China's (Shanghai) Galvanized Coil Price, 2014-2017 - China's Cold-rolled Thin Sheet Output and Sales Volume, 2010-2017 - China's (Shanghai, Tianjin, Guangzhou) Cold-rolled Coil Price, 2016-2017 - China's Natural Rubber Spot and Future Price, 2012-2017 - China's Investment in Fixed Assets, 2010-2017 - China's Investment in Real Estate Development, 2010-2017 - China's New Housing Start Area and Sales Area, 2005-2017 - China's Highway Freight Volume and Turnover, 2005-2017 - FAW Jiefang Automotive's Heavy Truck Output and Sales Volume, 2010-2017 - FAW Jiefang Automotive's Medium Truck Output and Sales Volume, 2010-2017 - FAW Jiefang Automotive's Light Truck Output and Sales Volume, 2010-2017 - FAW Jiefang Automotive's Mini Truck Output and Sales Volume, 2010-2017 - Main Natural Gas Trucks of FAW Jiefang Automotive - Main Truck Production Bases of FAW Group - Sinotruk's Revenue and Net Income, 2010-2016 - Sinotruk's Gross Margin, 2010-2016 - Sinotruk's Revenue Structure by Business, 2016 - Sinotruk's Heavy Truck Output and Sales Volume, 2010-2017 - Sinotruk's Medium Truck Output and Sales Volume, 2010-2017 - Sinotruk's Light Truck Output and Sales Volume, 2010-2017 - Sinotruk's Heavy Truck Product Family Genealogy - Sinotruk's Main Product Configuration - Dongfeng Motor's Revenue and Net Income, 2011-2016 - Dongfeng Motor's Gross Profit and Gross Margin, 2011-2016 - Dongfeng Motor's Revenue Breakdown by Business, 2015-2016 - Dongfeng Motor's Heavy Truck Output and Sales Volume, 2010-2017 - Dongfeng Motor's Medium Truck Output and Sales Volume, 2010-2017 - Dongfeng Motor's Light Truck Output and Sales Volume, 2010-2017 - Dongfeng Motor's Mini Truck Output and Sales Volume, 2010-2017 - Truck Capacity Distribution of Dongfeng Motor - Beiqi Foton Motor's Revenue and Net Income, 2010-2016 - Beiqi Foton Motor's Gross Margin, 2010-2016 - Beiqi Foton Motor's Revenue Breakdown and Gross Margin by Business, 2014-2016 - Heavy Truck Output and Sales Volume of BAIC Group (Beiqi Foton Motor), 2010-2017 - Medium Truck Output and Sales Volume of BAIC Group (Beiqi Foton Motor), 2010-2017 - BAIC Group's Light Truck Output and Sales Volume, 2010-2017 - BAIC Group's Mini Truck Output and Sales Volume, 2010-2017 - Truck Capacity Distribution of Beiqi Foton Motor - Capacity of Beijing Foton Daimler, 2016 - Main Heavy Trucks of Shaanxi Automobile Group - Shaanxi Automobile Group's Heavy Truck Output and Sales Volume, 2010-2017 - Shaanxi Automobile Group's Medium Truck Output and Sales Volume, 2010-2017 - Shaanxi Automobile Group's Light Truck Output and Sales Volume, 2010-2017 - JAC's Revenue and Net Income, 2010-2016 - JAC's Gross Margin, 2010-2016 - JAC's Revenue Structure and Gross Margin by Product, 2016 - JAC's Heavy Truck Output and Sales Volume, 2010-2017 - JAC's Medium Truck Output and Sales Volume, 2010-2017 - JAC's Light Truck Output and Sales Volume, 2010-2017 - Truck Capacity Distribution of JAC, 2016 - Hualing Xingma Automobile's Assets and Net Income, 2012-2016 - Hualing Xingma Automobile's Products Series - Hualing Xingma Automobile's Truck Output and Sales Volume, 2015-2016 - Hualing Xingma Automobile's Truck Sales at Home and Abroad, 2015-2016 - Qingling Motors' Revenue and Net Income, 2010-2016 - Qingling Motors' Gross Margin, 2010-2016 - Qingling Motors' Revenue Breakdown by Product, 2015-2016 - Qingling Motors' Heavy Truck Output and Sales Volume, 2010-2017 - Qingling Motors' Medium Truck Output and Sales Volume, 2010-2017 - Qingling Motors' Light Truck Output and Sales Volume, 2010-2017 - Jiangling Motors' Revenue and Net Income, 2010-2016 - Jiangling Motors' Gross Margin, 2010-2016 - Jiangling Motors' Revenue Structure by Product, 2015-2016 - Jiangling Motors' Light Truck Output and Sales Volume, 2010-2017 - Truck Capacity Distribution of Jiangling Motors, 2016 - Development History of SAIC GM Wuling - Main Trucks (Mini Trucks) of SAIC GM Wuling - SAIC GM Wuling's Mini Truck Output and Sales Volume, 2010-2017 - Distribution of SAIC GM Wuling's Production Bases - SAIC-IVECO Hongyan's Heavy Truck Output and Sales Volume, 2010-2017 - SAIC-IVECO Hongyan's Sales Target, 2017 - Main Heavy Trucks of Hubei Tri-Ring Special Vehicle - Hubei Tri-Ring Special Vehicle's Heavy Truck Output and Sales Volume, 2010-2017 - Hubei Tri-Ring Special Vehicle's Medium Truck Output and Sales Volume, 2010-2017 - Hubei Tri-Ring Special Vehicle's Light Truck Output and Sales Volume, 2010-2017 - XCMG Automobile's Heavy Truck Output and Sales Volume, 2010-2017 - Truck Capacity Distribution of XCMG Automobile, 2016 - GAC Hino Motors' Assets, Liabilities, and Revenue, 2012-2016 - GAC Hino Motors' Heavy Truck Output and Sales Volume, 2010-2017 - GAC Hino Motors' Capacity, 2016 - Zhejiang Feidie Automobile Manufacturing's Heavy Truck Output and Sales Volume, 2010-2017 - Zhejiang Feidie Automobile Manufacturing's Medium Truck Output and Sales Volume, 2010-2017 - Zhejiang Feidie Automobile Manufacturing's Light Truck Output and Sales Volume, 2010-2017 - Baotou Bei Ben Heavy-Duty Truck's Truck Output and Sales Volume, 2010-2017 - Shanxi Dayun Automobile Manufacturing's Heavy Truck Output and Sales Volume, 2010-2017 - Shanxi Dayun Automobile Manufacturing's Medium Truck Output and Sales Volume, 2010-2017 - Shanxi Dayun Automobile Manufacturing's Light Truck Output and Sales Volume, 2010-2017 - Truck Sales Growth in China, 2011-2021E - China's Truck Market Structure, 2010-2021E - Market Share of Top10 Truck Manufacturers in China, 2016 - Beijing Tiantan Biological Products Co., Ltd. (TIANTANBIO) - China Biologic Products, Inc. (NASDAQ: CBPO) - Green Cross China - Guizhou Taibang Biological Products Co., Ltd. - Hualan Biological Engineering,Inc. - Humanwell Healthcare Group Co., Ltd. - Jiangxi Boya Bio-Pharmaceutical Co., Ltd. - Shandong Taibang Biological Products Co., Ltd. - Shanghai Institute of Biological Products Co., Ltd. - Shanghai RAAS Blood Products Co., Ltd. - Shanxi Kangbao Biological Product Co., Ltd. - Shenzhen Weiguang Biological Products Co., Ltd. - Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. - Walvax Biotechnology Co, Ltd. - Xi'an Huitian Blood Products Co., Ltd. - Zhenxing Biopharmaceutical & Chemical Co., Ltd. For more information about this report visit http://www.researchandmarkets.com/research/2dng4t/china_blood Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/china-blood-product-industry-report-2017-product-market-size-expected-to-hit-rmb475-billion-in-2021---research-and-markets-300459175.html


PubMed | Jiangxi University of Traditional Chinese Medicine, Humanwell Healthcare Group Co. and Huazhong University of Science and Technology
Type: Journal Article | Journal: Bioanalysis | Year: 2016

Amitriptyline is a widely used tricyclic antidepressant, but the metabolic studies were conducted almost 20 years ago using high-performance liquid chromatography coupled with ultraviolet detector or radiolabeled methods.First, multiple ion monitoring (MIM)- enhanced product ion (EPI) scan was used to obtain the diagnostic ions or neutral losses in human liver microsome incubations with amitriptyline. Subsequently, predicted multiple reaction monitoring (MRM)-EPI scan was used to identify the metabolites in human urine with the diagnostic ions or neutral losses. Finally, product ion filtering and neutral loss filtering were used as the data mining tools to screen metabolites. Consequently, a total of 28 metabolites were identified in human urine after an oral administration using LC-MS/MS.An integrated workflow using LC-MS/MS was developed to comprehensively profile the metabolites of amitriptyline in human urine, in which five N-acetyl-l-cysteine conjugates were characterized as tentative biomarkers for idiosyncratic toxicity.


PubMed | Jiangxi University of Traditional Chinese Medicine, Hubei University of Chinese Medicine, Humanwell Healthcare Group Co. and Huazhong University of Science and Technology
Type: | Journal: Talanta | Year: 2016

The methods for detecting endogenous phospholipids (PL) are focused on the use of liquid chromatography-tandem mass spectrometry (LC-MS/MS). Since the structural relation and similar core structure of glycerophospholipids results in a common and predictable mass spectrometric fragmentation behavior, in the present study, six classes of lysoglycerophospholipid (Lyso-PL) were subjected to a predict-verify approach by multiple reaction monitoring (MRM) mode based on liquid chromatography-quadrupole linear ion trap mass spectrometry (LC-QTRAP-MS/MS) complemented with liquid chromatography-quadrupole time of flight mass spectrometry (LC-QTOF-MS/MS) in biological serum samples. A targeted metabolite profile of Lyso-PL was established and represented in the form of a LC-QTRAP-MRM analysis. There were total of 96 Lyso-PL molecular species, consisting of 317 regioisomers detected in serum of human and four rodent species. In addition, the metabolite profile was successfully applied to the analysis of qualitative distribution of Lyso-PLs in serum of human and four rodent species. We believe that this improvement in the method for qualitative analysis of endogenous Lyso-PLs should greatly contribute to identifying the role of lipid molecular species in biological systems. Also, the integrated strategy for establishment of metabolite profile can be applied to targeted qualitative analysis of other endogenous metabolites which occur in a high individual number but sharing either structural similarities or similar functional groups.


PubMed | Jiangxi University of Traditional Chinese Medicine, Humanwell Healthcare Group Co. and Huazhong University of Science and Technology
Type: | Journal: Journal of ethnopharmacology | Year: 2016

Alismatis rhizoma (AR), a Traditional Chinese Medicine with lipid-regulating properties, is usually used to treat hyperlipidemia. Lysophosphatidylcholines (Lyso PCs) play a crucial role in lipid metabolism disorders. In this study, the triterpene fraction purified from boiling water extract of AR was evaluated for its lipid lowering activity using mice with high-fat diet (HFD) induced hyperlipidemia. The metabolic changes of individual Lyso PCs treated with the triterpene fraction were detected by ultra-high performance liquid chromatography-triple quadrupole-linear ion trap mass spectrometer (UHPLC-QTRAP-MS/MS).HFD induced hyperlipidemia mice were administrated with triterpene and non-triterpene fractions at doses of 180, 360 and 720 mg/kg body weight/day for 4 weeks, respectively. Total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and atherogenic Index (AI) in mice serum were measured. The chemical components in the lipid-lowering fraction were characterized by ultra-high performance liquid chromatography-quadrupole time of flight tandem mass spectrometry (UHPLC-QTOF-MS/MS). The changes of Lyso PC in the serum of mice treated with the lipid-lowering fraction were quantified by UHPLC-QTRAP-MS/MS.A total of 18 alisol derivatives were identified in the triterpene fraction. The hyperlipidemia mice treated with the triterpene fraction showed a significant decrease in serum TC, LDL-C and AI after continuous consumption of HFD for 4 weeks. The results also showed that 27 serum Lyso PCs in mice fed with HFD were down-regulated, and 19 were up-regulated. The abnormal serum level of Lyso PCs associated with hyperlipidemia was intervened by the alisol derivatives, with increase of unsaturated Lyso PCs and decrease of saturated ones.The study demonstrated for the first time that triterpenes from the AR extract can lower serum lipid level in HFD induced hyperlipidemia mice. These metabolism changes of Lyso PCs could further improve our understanding of the potential mechanism of lipid lowering effect of AR.


Patent
Wuhan Optics Valley Humanwell Bio pharmaceutical Co., Hubei Bio Pharmaceutical Industrial Technological Institute Inc., Wuhan Chemligand Bio Pharmaceutical Co. and Humanwell Healthcare Group Co. | Date: 2016-10-12

A capsule containing total flavonoids of Desmodium styracifolium, a method for preparing the same and a use of the capsule containing total flavonoids of Desmodium styracifolium are provided. Specifically, the capsule includes total flavonoids of Desmodium Styracifolium provided in a form of alcohol extract of Desmodium Styracifolium and a pharmaceutically acceptable excipient.


A capsule containing total flavonoids of Desmodium styracifolium, a method for preparing the same and a use of the capsule containing total flavonoids of Desmodium styracifolium are provided. Specifically, the capsule includes total flavonoids of Desmodium Styracifolium provided in a form of alcohol extract of Desmodium Styracifolium and a pharmaceutically acceptable excipient.


Patent
Humanwell Healthcare Group Co. | Date: 2014-07-15

Disclosed are a pharmaceutical composition, a method for preparing the same and use thereof. The pharmaceutical composition consists of total flavonoids of Desmodium Styracifolium as an active ingredient and a pharmaceutically acceptable excipient. The pharmaceutical composition can be formulated in a form of a medicament formulation suitable to administration in clinic, and can be used in preparation of clinic treatment medicaments for treating dampness-heat and urinary stone (stagnation of dampness-heat).

Loading Humanwell Healthcare Group Co. collaborators
Loading Humanwell Healthcare Group Co. collaborators